The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•20 March 2026•

1 min read

Novartis Bolsters Oncology Pipeline with Acquisition of Breast Cancer Drug Candidate

Key Facts

1Novartis entered into an agreement with Synnovation Therapeutics to acquire SNV4818.

2The target drug is a pan-mutant-selective PI3Kα inhibitor for HR+/HER2- breast cancer treatment.

Version History

3 additional sources confirmed this story

Novartis has entered into a strategic agreement with Synnovation Therapeutics to acquire SNV4818, a promising experimental drug candidate. The asset is a pan-mutant-selective PI3Kα inhibitor specifically designed to treat advanced HR+/HER2- breast cancer. This acquisition underscores Novartis's commitment to expanding its leadership in the oncology sector by integrating next-generation therapeutic approaches. Beyond breast cancer, the company aims to explore the drug's potential in treating various other solid tumor indications. Analysts view this move as a positive step in strengthening the company's core franchise, signaling continued investment in high-growth therapeutic areas. The deal reflects a broader industry trend of pharmaceutical giants securing specialized biotech assets to drive long-term innovation.